Abstract
We investigated the use of tazobactam/piperacillin (TAZ/PIPC) and its relation to resistant bacteria in our hospital over the past five years. In outpatients, major gram-negative bacilli susceptibility rates remained above 95%. In hospitalized patients, particularly those with ESBL-producing Escherichia coli, Klebsiella oxytoca, and Pseudomonas aeruginosa, the respective rates were 90.9% (50/55), 81.1% (30/37), and 80.9% (72/89) in 2021. TAZ/PIPC-intermediate/resistant strains were identified more frequently in patients who had received TAZ/PIPC within the past 3 months (22/29 vs. 18/152, p ＜ 0.01), and the number of administration days was also significantly longer (13.3 vs. 8.2 days, p ＜ 0.05). Based on the aforementioned findings, we believed that TAZ/PIPC should be administered only for about a week, followed by de-escalation.
